An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Athira Pharma to Participate in Jefferies London Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Athira Pharma, Inc. (NASDAQ: ATHA) announces participation at Jefferies London Healthcare Conference. The late clinical-stage biopharmaceutical company will hold a Fireside Chat on November 16, 2023, to discuss small molecule development for neuronal health and neurodegeneration. A live webcast and archived replay will be available on the Athira website.
Positive
None.
Negative
None.
BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023, in London. Details are as follows:
Jefferies London Healthcare Conference Format: Fireside Chat Date and Time: Thursday, November 16, 2023, from 1:30 pm - 1:55 pm GMT Location: Waldorf Hilton, London
About Athira Pharma, Inc. Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological disease by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on X, formerly known as Twitter, and Instagram.
What is the event Athira Pharma, Inc. is participating in?
Athira Pharma, Inc. is participating in the Jefferies London Healthcare Conference.
When will the Fireside Chat take place?
The Fireside Chat will take place on Thursday, November 16, 2023, from 1:30 pm - 1:55 pm GMT.
Where can the live webcast of the Fireside Chat be accessed?
The live webcast can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor.
Will there be an archived replay of the event available?
Yes, an archived replay will be available for at least 30 days following the event.
m3 biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. the lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. the company’s research has been funded by the alzheimer’s drug discovery foundation, washington’s life sciences discovery fund, w fund, wrf capital, dolby family ventures and other private investors. where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, m3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of alzheimer
